Retrovirally mediated correction of bone marrow-derived mesenchymal stem cells from patients with mucopolysaccharidosis type I.
Baxter, Melissa A Wynn, Robert F Deakin, Jon A Bellantuono, Ilaria Edington, Kirsten G Cooper, Alan Besley, Guy T N Church, Heather J Wraith, J Ed Carr, Trevor F
Baxter, Melissa A
Wynn, Robert F
Deakin, Jon A
Bellantuono, Ilaria
Edington, Kirsten G
Cooper, Alan
Besley, Guy T N
Church, Heather J
Wraith, J Ed
Carr, Trevor F
Citations
Altmetric:
Abstract
We have investigated the utility of bone marrow-derived mesenchymal stem cells (MSCs) as targets for gene therapy of the autosomal recessive disorder mucopolysaccharidosis type IH (MPS-IH, Hurler syndrome). Cultures of MSCs were initially exposed to a green fluorescent protein-expressing retrovirus. Green fluorescent protein-positive cells maintained their proliferative and differentiation capacity. Next we used a vector encoding alpha-L-iduronidase (IDUA), the enzyme that is defective in MPS-IH. Following transduction, MPS-IH MSCs expressed high levels of IDUA and secreted supernormal levels of this enzyme into the extracellular medium. Exogenous IDUA expression led to a normalization of glycosaminoglycan storage in MPS-IH cells, as evidenced by a dramatic decrease in the amount of (35)SO(4) sequestered within the heparan sulfate and dermatan sulfate compartments of these cells. Finally, gene-modified MSCs were able to cross-correct the enzyme defect in untransduced MPS-IH fibroblasts via protein transfer.
Description
Date
2002-03-01
Publisher
Collections
Keywords
Type
Article
Citation
Retrovirally mediated correction of bone marrow-derived mesenchymal stem cells from patients with mucopolysaccharidosis type I. 2002, 99 (5):1857-9 Blood